.
Coeptis Pharmaceuticals is headquartered in Wexford, Pennsylvania.
Coeptis Pharmaceuticals is a life science company.
Join Mergr to view all 0 acquisitions of life science companies in , including .
105 Bradford Rd Suite 420,
Wexford, Pennsylvania
15090
United States,
(724) 934-6467
www.coeptispharma.com
Coeptis Pharmaceuticals, Inc. is a privately held biopharmaceutical company engaged in the acquisition, development, and commercialization of innovative products that are developed via the 505(b)2 pathways. Coeptis recently acquired FDA-approved Consensi™ (a combination of amlodipine and celecoxib), which is indicated for patients for whom treatment with amlodipine for hypertension and celecoxib for osteoarthritis are appropriate and plans to launch Consensi™ later this year.
| Year | ≤ '19 | '20 | '21 | '22 | '23 | '24 | T | |
|---|---|---|---|---|---|---|---|---|
| Buy (0.0/yr) | # | - | - | - | - | - | - | 0 |
| Sell (0.0/yr) | # | 1 | - | - | - | - | - | 1 |
| vol | $14M | $14M | ||||||
| 1 | ||||||||
| Company | Date | Value | Type |
|---|---|---|---|
| Coeptis Pharmaceuticals, Inc. - Seven Development Stage Drug Products | 2019-06-18 | 14M USD | Divestiture |
| Wexford, Pennsylvania | |||
| View All >> | |||
| Sector | Buy # | Value | Sell # | Value | |
|---|---|---|---|---|---|
| Life Science | - | - | 1 (100%) | 14M (100%) | |
| Total | - | - | 1 | $14M | |
| State/Country | Buy | Value | Sell | Value | ||
|---|---|---|---|---|---|---|
| United States | - | - | 1 | 14M | ||
| Pennsylvania | - | - | 1 | 14M | ||
| Total | - | - | 1 | $14M | ||
| sell | # | Total |
|---|---|---|
| < $100M | 1 | $14M |
| TOTAL | $14M | |
| Largest |
Coeptis Pharmaceuticals, Inc. - Seven Development Stage Drug Products $14M (2019-06-18) |
|
| Deals | ||
|---|---|---|
| Divested to | ||
| Strategic(s) |
|
1 (100%) |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.
Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.
Try us for 1 week free today!
No obligation. Cancel anytime.
